HomeSGX-LISTED COMPANIESLion Asiapac: Q4 and FY2025 Loss

Lion Asiapac: Q4 and FY2025 Loss

Published on

spot_img

Lion Asiapac Limited is set to report a loss for the fourth quarter and the full year ended 30 June 2025, primarily due to a downturn in its trading business. The Group has reclassified Compact Energy Sdn Bhd as a discontinued operation following a proposed disposal, with the results presented separately. This strategic move, which has received shareholder approval, is expected to be completed in early September 2025. Moving forward, the Group will concentrate on its ‘Supply Roofing Solutions’ and remaining trading businesses amidst an uncertain economic outlook.

• A significant corporate restructuring is underway, pivoting the Group’s core business operations

• The company faced a challenging financial period, experiencing a notable shift from previous performance

• Changes in market demand for key products heavily influenced the Group’s overall financial outcome

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...